Cariprazine in Hospital Treatment of Acute Psychotic Conditions Due to Comorbid Schizophrenia and Chemical Addictions

Background: endogenous psychoses complicated with different addictions have special psychopathological structure including delirious episodes, true hallucinations combined with typical positive symptoms of schizophrenia. These cases are difficult for treatment due to non-compliance of patients and their bad tolerance to drugs. The aim was to study the most effective psychopharmacological treatment using cariprazine for acute psychotic states in paranoid schizophrenia combined with chemical addictions. Patients and Methods: the study was conducted at psychiatric hospitals of Tomsk region, St. Petersburg, Nizhnevartovsk and Noyabrsk from 2018 to 2024. 208 men aged 18 to 45 years suffering from paranoid schizophrenia and dependent on psychoactive substances were examined. The main group made up 104 in-patients, who took cariprazine alone or in combination with haloperidol or chlorpromazine. The control group included 104 in-patients treated with other antipsychotics (aripiprazole, risperidone, olanzapine). Research methods: clinical and psychopathological, psychometric (PANSS, SANS, CGI, GAF), statistical (Python 3.11.0; R version 3.2.4; SPSS Statistics Base 22.0). Results: It was revealed that when comparing the control group with the main group, similar indicators were observed on the CGI and GAF scales on the 2nd week of the study, and on the 4th week of the study, compared with the control group, an improvement in indicators on the PANSS, SANS, CGI, GAF scales was observed. Conclusions: Cariprazine, compared with other atypical antipsychotics (risperidone, olanzapine, aripiprazole), showed a distinct antipsychotic effect in the treatment of acute psychotic states in patients with schizophrenia dependent on psychoactive substances. By the end of the 2nd week after hospitalization, when treating with cariprazine at an average dose of 3 to 6 mg/day in combination with typical neuroleptics (haloperidol, chlorpromazine) or a tranquilizer, the most pronounced antipsychotic effect is achieved. Subsequent isolated use of cariprazine at a therapeutic dose of 3–4.5 mg/day has an effect similar to that of leading atypical antipsychotics by the end of the 4th week of treatment. Unlike other atypical antipsychotics, cariprazine was more effective in the treatment of negative symptoms of schizophrenia, which made it possible to achieve an improvement in overall functioning, increase the duration of remission, and reduce the risk of rehospitalization and the development of hospitalism.

1. World Drug Report 2023. Booklet 1 - Executive summary. Policy implications. (United Nations publication, Sales No. E.23.XI.7). https://www.unodc.org/res/WDR-2023/WDR23_ExSum_Russian.pdf (accessed 07.07.2024).

2. Buleyko AA, Soldatkin VA. Impact of alcohol abuse on suicide risk in schizophrenic patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10):144-148. (In Russ.). doi: 10.17116/jnevro2021121101144

3. Boсhan NA, Semke VYa. Co-morbidity in Addiction Psychiatry. Tomsk: Publishing House of Tomsk University, 2009:510. (In Russ.). ISBN 978-5-7511-1922-6.

4. Bokhan NA, Selivanov GYu. Psychiatric Comorbidity and Synthetic Cannabinoid (Spice) Abuse Syndrome. Journal of Concurrent Disorders. 2023;5(2):12-33. doi: 10.54127/FDAE6631

5. Tolmacheva VA, Kiseleva MG, Chernov NV, Kostyuk GP. Features of cognitive impairment in individuals with paranoid schizophrenia combined with alcohol dependence syndrome S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):73-76. (In Russ.). doi: 10.17116/jnevro202112111173

6. Ivanets NN, Vinnikova MA, Ezhkova EV, Titkov MS, Bulatova RA. Clinical presentations and therapy of polysubstance dependence in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):63-69. (In Russ.). doi: 10.17116/jnevro202112104163

7. Frolova V.I. The experience of using cariprazine in the treatment of schizophrenia and bipolar affective disorder. Psychiatry and psychopharmacotherapy. 2023;25(6):28-33. (In Russ.).

8. Ivanov SV, Voronova EI. The newer antipsychotic cariprazine (Reagila): perspectives for use in different stages of schizophrenia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):139-144. (In Russ.). doi: 10.17116/jnevro2021121091139

9. Bokhan NA, Selivanov GYu, Blonsky KA. Preventive emergency therapy for psychiatric disorders comorbid with synthetic cannabinoid abuse. Narcology. 2022;21(5):16-24. (In Russ.). doi: 10.25557/1682-8313.2022.05.16-24

10. Bokhan NA, Selivanov GYu. Aggression aimed at oneself in cases of mental disorders comorbid with abuse of synthetic cannabinoids (spices). Rossijskij Psihiatriceskij Zurnal. 2023;3:76-90. (In Russ.).

11. Medvedev VE. Cariprazine - a New Drug for Treatment of Schizophrenia and Bipolar Disorder. Current Therapy of Mental Disorders 2022;3:51-57. (In Russ.). doi: 10.21265/PSYPH.2022.46.63.006

12. Chumakov EM. Current non-pharmacological and pharmacological treatment strategies for schizophrenia aimed at improving compliance. Current Therapy of Mental Disorders. 2022;3:58-66. (In Russ.). doi: 10.21265/PSYPH.2022.97.90.007

13. Alegría M, Frank RG, Hansen HB, Sharfstein JM, Shim RS, Tierney M. Transforming Mental Health And Addiction Services. Health Aff (Millwood). 2021 Feb;40(2):226-234. doi: 10.1377/hlthaff.2020.01472 Epub 2021 Jan 21. PMID: 33476189.

14. Karno MP, Rawson R, Rogers B, Spear S, Grella C, Mooney LJ, Saitz R, Kagan B, Glasner S. Effect of screening, brief intervention and referral to treatment for unhealthy alcohol and other drug use in mental health treatment settings: a randomized controlled trial. Addiction. 2021;116(1):159-169. doi: 10.1111/add.15114

15. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Heres S, Kissling W, Davis JM, Leucht S. Maintenance Treatment with Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. Schizophr Bull. 2022 Jun 21;48(4):738-740. doi: 10.1093/schbul/sbac041 PMID: 35556140; PMCID: PMC9212092.

16. Hjorth S. The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia from a Pharmacology Perspective. Front Psychiatry. 2021 24;12:760181. doi: 10.3389/fpsyt.2021.760181 PMID: 34899422; PMCID: PMC8652414.

17. Lähteenvuo M, Batalla A, Luykx JJ, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J, Taipale H. Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatr Scand. 2021;144(1):42-49. doi: 10.1111/acps.13291 Epub 2021 Mar 8. PMID: 33650123; PMCID: PMC8359349.

18. Ovchinnikov AA, Sultanova AN, Stankevich AS, Narov MYu, Chut UYu, Ioanidi DK, Lugovenko VA. Features of addictive disorders and affective symptoms in schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2021;2(111):23-31. (In Russ.). doi: 10.26617/1810-3111-2021-2(111)-23-31.

19. Bokhan NA, Selivanov GYu. Paranoid schizophrenia and dependence on synthetic cannabinoids. Tomsk: Printing House Integrated Casework. 2024:252. (In Russ.). ISBN 978-5-907509-52-8

20. Shamrey VK, Markov AV, Kurasov ES, Kolchev AI. Phenomenology of mental disorders in users of synthetic cathinones. Social and clinical psychiatry. 2022;32(1):102-109. (In Russ.).

21. Samoylova DD, Barylnik YuB. The complex assessment of state and treatment results of patients with paranoid schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry 2021;121(1):59-64. (In Russ.). doi: 10.17116/jnevro202112101159

22. Nasyrova RF, Neznanov NG, Schneider NA, Petrova MM. Drug-induced long QT syndrome in psychiatry and neurology. SPb.: DEAN Publishing House. 2024:592. (In Russ.). ISBN 978-5-6051473-9-8.